UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, DC 20549
FORM 8-A
FOR REGISTRATION OF CERTAIN CLASSES OF SECURITIES
PURSUANT TO SECTION 12(b) OR 12(g) OF THE
SECURITIES EXCHANGE ACT OF 1934
Strongbridge Biopharma plc
(formerly known as Cortendo plc)
(Exact name of registrant as specified in its charter)
Ireland
|
|
Not Applicable
|
900 Northbrook Drive
Suite 200
Trevose, Pennsylvania 19053
(Address of principal executive offices) (Zip Code)
Securities to be register to Section 12(b) of the Act:
Title of each class
|
|
Name of each exchange on which each class
|
Ordinary Shares, par value $0.01 per share |
|
The NASDAQ Stock Market LLC |
If this form relates to the registration of a class of securities pursuant to Section 12(b) of the Exchange Act and is effective pursuant to General Instruction A.(c), check the following box. x
If this form relates to the registration of a class of securities pursuant to Section 12(g) of the Exchange Act and is effective pursuant to General Instruction A.(d), check the following box. o
Securities Act registration statement file number to which this form relates: 333-206654
Securities to be registered pursuant to Section 12(g) of the Act: None
ITEM 1. DESCRIPTION OF REGISTRANTS SECURITIES TO BE REGISTERED
Strongbridge Biopharma plc (the Registrant) hereby incorporates by reference herein the description of its Ordinary Shares, par value $0.01 per share, to be registered hereunder, contained under the heading Description of Share Capital and Articles of Association in the Registrants Registration Statement on Form F-1 (File No. 333-206654), as originally filed with the Securities and Exchange Commission (the Commission) on August 28, 2015, including exhibits, and as amended from time to time thereafter (the Registration Statement). In addition, the above-referenced description included in any prospectus relating to the Registration Statement filed with the Commission pursuant to Rule 424(b) under the Securities Act of 1933, as amended, shall be deemed to be incorporated by reference herein.
ITEM 2. EXHIBITS
In accordance with the Instructions as to Exhibits with respect to Form 8-A, no exhibits are required to be filed as part of this registration statement because no other securities of the Registrant are registered on The NASDAQ Stock Market LLC and the securities registered hereby are not being registered pursuant to Section 12(g) of the Securities Exchange Act of 1934, as amended.
SIGNATURE
Pursuant to the requirements of Section 12 of the Securities Exchange Act of 1934, the Registrant has duly caused this Registration Statement to be signed on its behalf by the undersigned, thereto duly authorized.
Dated: September 25, 2015
|
STRONGBRIDGE BIOPHARMA PLC |
|
|
|
|
|
|
|
|
By: |
/s/ Matthew Pauls |
|
|
Matthew Pauls, Chief Executive Officer |